Aims: The aim of this multicentre, non-randomised trial was to evaluate the safety and efficacy at 180±14 days of a pimecrolimus eluting coronary stent based on a cobalt-chromium platform a
1. Middelheim Hospital Antwerp, Belgium; 2. Cardiovascular Center Aalst, Belgium; 3. HELIOS Klinikum Siegburg, Germany; 4. Schwarzwald-Baar Klinikum Villingen-Schwenningen, Germany; 5. University Hospital Antwerp, Belgium; 6. Genae Associates Antwerp, Bel
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Read next articlePrognostic heterogeneity among patients with chronic stable coronary disease: determinants of long-term mortality after treatment with percutaneous intervention